Sight-robbing injuries to the cornea can be repaired using a groundbreaking experimental stem cell treatment, a new study ...

The “off-the-shelf” CAR T-cell therapy CTD402 will be evaluated in a phase 1b/2 trial for patients with T-cell acute ...

Chimeric antigen receptor T-cell therapy improves not only lupus disease activity but also other related conditions that ...

Immuno-oncology and cell-based treatments, which harness the body's own immune system to combat illnesses like cancer, have ...

Scientists may have unlocked a new milestone in cancer treatment. An individual who received CAR T-cell therapy has been in ...

The growing incidence of genetic disorders and chronic illnesses, including cancer and rare inherited conditions, is fueling the demand for advanced therapies, highlighting the need for strong ...

An expanded phase clinical trial that tested a groundbreaking, experimental stem cell treatment for blinding cornea injuries ...

Enrich Biosystems, a Branford-based life science tool company, today announced the appointment of Laszlo G Radvanyi, Ph.D. as scientific advisor. Dr. Radvanyi, a Professor in the Department of ...

Culver City-based ImmunityBio, Inc., a leading immunotherapy company, has announced that the U.S. Food and Drug ...

Phase 1 Dose Expansion Initiated for FT819 Off-the-Shelf CAR T-cell Product Candidate with Fludarabine-free Conditioning in Moderate-to-Severe ...

Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...

One of the pioneers of CAR T-cell therapy, Dr. Brentjens spoke with Becker's about what the new facility means for cancer innovation, as well as on how leaders across the U.S. can best integrate CAR T ...